HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results.

AbstractAIM:
Neuroendocrine tumors over-express somatostatin receptors and literature data have demonstrated the efficacy of the peptide receptor radionuclide therapy with somatostatin analogues labelled with high activities of b-emitting radioisotopes, such as (90)Y and (177)Lu. Yttrium-90 is a pure high energy b-emitter while (177)Lu is a b/g emitter of medium energy. We decided to evaluate an original tandem treatment based on administration of radiolabeled [DOTA(0),Tyr(3)]octreotate (DOTA-TATE) alternating (177)Lu and 90Y. Aim of this study was to evaluate the feasibility, the efficacy and the toxicity of this treatment in neuroendocrine tumors expressing somatostatin receptors relapsed or refractory to conventional therapies.
METHODS:
Patients were treated with four therapeutic cycles alternating [(177)Lu]DOTA-TATE (5.55 GBq) and [(90)Y]DOTA-TATE (2.6 GBq). Dosimetric evaluation after administration of [(177)Lu]DOTA-TATE allows to calculate the absorbed doses in healthy organs. Blood samples were collected at 5 min, 1, 6, 24, 48, 72, 96 h and scintigraphy was performed once a day for four days after administration. Toxicity was evaluated considering hematological parameters and renal toxicity was evaluated also by the glomerular filtration rate (GFR). Efficacy related with RECIST criteria.
RESULTS:
Up to now 26 patients entered the study and 16 patients completed all cycles. Treatment was well tolerated with no adverse event registered. No damage to healthy organs was revealed in accordance with the calculated absorbed doses. We had a partial response in 10/15 patients evaluated three months after the fourth treatment.
CONCLUSIONS:
Up to now only a few patients participated in and concluded this study; preliminary results are encouraging and indicate the feasibility of the study.
AuthorsE Seregni, M Maccauro, A Coliva, M R Castellani, E Bajetta, G Aliberti, C Vellani, C Chiesa, A Martinetti, A Bogni, E Bombardieri
JournalThe quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology (Q J Nucl Med Mol Imaging) Vol. 54 Issue 1 Pg. 84-91 (Feb 2010) ISSN: 1824-4785 [Print] Italy
PMID20168290 (Publication Type: Clinical Trial, Phase II, Journal Article)
Chemical References
  • (177lutetium-DOTA(O)Tyr3)octreotate
  • 90Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)-
  • Organometallic Compounds
  • Octreotide
Topics
  • Adult
  • Aged
  • Drug Therapy, Combination
  • Humans
  • Male
  • Middle Aged
  • Neuroendocrine Tumors (pathology, radiotherapy, therapy)
  • Octreotide (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
  • Organometallic Compounds (administration & dosage, adverse effects, therapeutic use)
  • Radiometry
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: